| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.098 | 0.007 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.008 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.008 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.008 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.008 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.14 | 0.009 |